Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 119

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 5
Chunk 119
---
ID/KIOVIG, HYQVIA, and CUVITRU,

Albumin products including HUMAN ALBUMIN and FLEXBUMIN

Oncology: ALUNBRIG, EXKIVITY (Takeda decided to voluntarily withdraw the product globally), FRUZAQLA

Other: QDENGA

Core Operating Profit

Core Operating Profit for the fiscal year ended March 31, 2024 was JPY 1,054.9 billion (JPY -133.5 billion and -11.2% AER, -13.3% CER). The components of Core Operating Profit are as below:

                                                                 Billion JPY or percentage                                                                                               
                                                                 For the fiscal year ended                                                 AER                                      CER  
                                                                 March 31,                                                                                                               
                                                                 2023                                          2024                        Amount of Change      % Change      % Change  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Core revenue                                                   ¥                                4,027.5      ¥              4,263.8      ¥                          5.9           1.5  
  Core cost of sales                                                                            (1,208.4)                   (1,426.3)      (217.9)                   18.0          13.0  
  Core selling, general and administrative (SG& A) expenses      (997.3)                                                    (1,053.0)      (55.6)                     5.6           0.8  
  Core research and development (R& D) expenses                  (633.4)                                       (729.6)                     (96.3)                    15.2           8.3  
  Core operating profit                                          ¥                                1,188.4      ¥              1,054.9      ¥                       (11.2)        (13.3)  

During the periods presented, these items fluctuated as follows:

Core Cost of Sales

Core Cost of Sales was JPY 1,426.3 billion (JPY +217.9 billion and +18.0% AER, +13.0% CER). The increase was primarily due to revenue growth in our key business areas with a change in product mix and the depreciation of Japanese yen as compared to the fiscal year ended March 31, 2023.

Core Selling, General and Administrative (SG& A) Expenses

Core SG& A